Peter Bossuyt - Concepedia

Author

Peter Bossuyt

Also Known As

A Van de Water, Abraham Bezuidenhout, Anurag Agrawal, BOSSUYT P, BOSSUYT P, Bossuyt, P., Bossuyt, P. M., Bossuyt, P. M. M., Bossuyt, P. M.M., Bossuyt, Peter

484

Publications

15.9K

Citations

H-Index

133

Concepts

All Affiliations

Imelda Hospital KU Leuven Amsterdam UMC Location University of Amsterdam AZ Delta University of Amsterdam

About

Peter Bossuyt is an author at Imelda Hospital specializing in medicine, gastroenterology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	53	5.5K
2	Public Health	8	10	664
3	Engineering	2	2	110
4	Health Sciences	2	2	400
5	Allergy	1	1	13

Peter Bossuyt

113

Publications

11.2K

Citations

H-Index

Page 1

	Year	Citations
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment Joana Torres, Stefanos Bonovas, Glen Doherty, Journal of Crohn s and Colitis	2019	1.3K
ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment Michel Adamina, Stefanos Bonovas, Tim Raine, Journal of Crohn s and Colitis	2019	1.1K
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial Jean‐Frédéric Colombel, Remo Panaccione, Peter Bossuyt, The Lancet GastroenterologyTight Control ManagementClinical GastroenterologyUlcerative ColitisMedicine	2017	883
European evidence based consensus for endoscopy in inflammatory bowel disease Vito Annese, Marco Daperno, Matthew D. Rutter, Journal of Crohn s and Colitis EndoscopyEcco MembersEuropean EvidencePatient SafetyGastroenterology	2013	796
The Clinical Meaning of Rankin ‘Handicap’ Grades After Stroke Rob de Haan, M. Limburg, Peter Bossuyt, Stroke	1995	451
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials Geert D’Haens, Remo Panaccione, Filip Baert, The Lancet RheumatologyInduction TherapyImmunologyGastroenterologyClinical Trials	2022	362
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection Miguel Regueiro, Brian G. Feagan, Bin Zou, Gastroenterology	2016	320
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease Geert D’Haens, Séverine Vermeire, Guy Lambrecht, Gastroenterology InflammationChronic Inflammatory DiseasesInfliximab DoseImmunologyGastroenterology	2018	295
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial Marc Ferrante, Remo Panaccione, Filip Baert, The Lancet Fortify Maintenance TrialRheumatologyWithdrawal Phase 3GastroenterologyTreatment Option	2022	294
Physical examination is sufficient for the diagnosis of sprained ankles C. Niek van Dijk, L. Lim, Peter Bossuyt, Journal of Bone and Joint Surgery - British Volume Inversion InjuryKinesiologyHealth SciencesDelayed Physical ExaminationSport Injury	1996	273

Page 1